US20190254336A1 - Liquid composition for electronic cigarettes - Google Patents
Liquid composition for electronic cigarettes Download PDFInfo
- Publication number
- US20190254336A1 US20190254336A1 US15/901,508 US201815901508A US2019254336A1 US 20190254336 A1 US20190254336 A1 US 20190254336A1 US 201815901508 A US201815901508 A US 201815901508A US 2019254336 A1 US2019254336 A1 US 2019254336A1
- Authority
- US
- United States
- Prior art keywords
- liquid composition
- stimulant
- electronic cigarettes
- vaporizable
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 239000007788 liquid Substances 0.000 title claims abstract description 37
- 239000003571 electronic cigarette Substances 0.000 title claims abstract description 29
- TXOFSCODFRHERQ-UHFFFAOYSA-N Dimethylphenethylamine Natural products CN(C)CCC1=CC=CC=C1 TXOFSCODFRHERQ-UHFFFAOYSA-N 0.000 claims description 16
- YAHRDLICUYEDAU-UHFFFAOYSA-N methylhexaneamine Chemical compound CCC(C)CC(C)N YAHRDLICUYEDAU-UHFFFAOYSA-N 0.000 claims description 14
- IZCBXLKODYZSDJ-UHFFFAOYSA-N 5-methylhexan-2-amine Chemical compound CC(C)CCC(C)N IZCBXLKODYZSDJ-UHFFFAOYSA-N 0.000 claims description 13
- QNIVIMYXGGFTAK-UHFFFAOYSA-N octodrine Chemical compound CC(C)CCCC(C)N QNIVIMYXGGFTAK-UHFFFAOYSA-N 0.000 claims description 13
- UNBMPKNTYKDYCG-UHFFFAOYSA-N 4-methylpentan-2-amine Chemical compound CC(C)CC(C)N UNBMPKNTYKDYCG-UHFFFAOYSA-N 0.000 claims description 12
- IGELDTXGMACMRK-UHFFFAOYSA-N 5-methylheptan-2-amine Chemical compound CCC(C)CCC(C)N IGELDTXGMACMRK-UHFFFAOYSA-N 0.000 claims description 11
- WZRCQWQRFZITDX-UHFFFAOYSA-N (RS)-norcoclaurine Chemical compound C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 WZRCQWQRFZITDX-UHFFFAOYSA-N 0.000 claims description 10
- WZRCQWQRFZITDX-AWEZNQCLSA-N Norcoclaurine Natural products C1=CC(O)=CC=C1C[C@H]1C2=CC(O)=C(O)C=C2CCN1 WZRCQWQRFZITDX-AWEZNQCLSA-N 0.000 claims description 10
- BVURNMLGDQYNAF-SECBINFHSA-N (1r)-n,n-dimethyl-1-phenylethanamine Chemical compound CN(C)[C@H](C)C1=CC=CC=C1 BVURNMLGDQYNAF-SECBINFHSA-N 0.000 claims description 7
- 239000000021 stimulant Substances 0.000 abstract description 16
- 239000000150 Sympathomimetic Substances 0.000 abstract description 7
- 230000001975 sympathomimetic effect Effects 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 8
- 229960002715 nicotine Drugs 0.000 description 8
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 8
- 229960002748 norepinephrine Drugs 0.000 description 8
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 8
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 229930182837 (R)-adrenaline Natural products 0.000 description 5
- 229960005139 epinephrine Drugs 0.000 description 5
- 230000036626 alertness Effects 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229950000752 methylhexaneamine Drugs 0.000 description 3
- 230000036314 physical performance Effects 0.000 description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229960001465 octodrine Drugs 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- LPULCTXGGDJCTO-UHFFFAOYSA-N 6-methylheptan-1-amine Chemical compound CC(C)CCCCCN LPULCTXGGDJCTO-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 241001517310 Eria Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- WGBBUURBHXLGFM-UHFFFAOYSA-N hexan-2-amine Chemical compound CCCCC(C)N WGBBUURBHXLGFM-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- VSRBKQFNFZQRBM-UHFFFAOYSA-N tuaminoheptane Chemical compound CCCCCC(C)N VSRBKQFNFZQRBM-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
Definitions
- the present invention relates a vaporizable liquid composition for use with smokeless electronic cigarettes (e-cigarettes). More particularly, the invention relates to a vaporizable liquid composition including a vaporizable base and a stimulant.
- U.S. Patent Application Publication No. US 2015/0150303 to Jensen discloses an electronic cigarette liquid including a vaporizable base, a flavoring and a non-nicotine stimulant.
- the non-nicotine stimulants disclosed in US 2015/0150303 are caffeine, guarana and kola nut.
- the invention relates to a vaporizable liquid composition for use with smokeless electronic cigarettes (e-cigarettes). More particularly, the invention relates to a vaporizable liquid composition including a vaporizable base and a stimulant.
- a stimulant incorporated into a liquid composition for electronic cigarettes according to an aspect of the invention may be 2-Amino-6-methylheptane.
- a stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be 2-Amino-5-methylhexane.
- a stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be 5-Methyl-2-heptanamine.
- a stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be Higenamine.
- a stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be 1,3-Dimethylamylamine.
- a stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be 1,3-Dimethylbutylamine.
- a stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be N,N-Dimethylphenethylamine.
- the liquid composition may include a sympathomimetic stimulant, which may mimic responses due to stimulation of sympathetic nerves and directly or indirectly activate adrenergic receptors by increasing certain naturally occurring catecholamines such as norepinephrine (noradrenaline), epinephrine (adrenaline) and dopamine levels.
- a sympathomimetic stimulant which may mimic responses due to stimulation of sympathetic nerves and directly or indirectly activate adrenergic receptors by increasing certain naturally occurring catecholamines such as norepinephrine (noradrenaline), epinephrine (adrenaline) and dopamine levels.
- a further advantage of a liquid composition for electronic cigarettes according to an aspect of the invention is that the liquid composition may incorporate a stimulant having the effects of enhancing energy, mental focus, alertness, overall cognitive function, and physical performance.
- FIG. 1 shows a chemical structure for nicotine
- FIG. 2 shows a chemical structure for caffeine
- FIG. 3 shows a chemical structure for 2-Amino-6-methylheptane
- FIG. 4 shows a chemical structure for 2-Amino-5-methylhexane
- FIG. 5 shows a chemical structure for 5-Methyl-2-heptanamine
- FIG. 6 shows a chemical structure for Higenamine
- FIG. 7 shows a chemical structure for 1,3-Dimethylamylamine
- FIG. 8 shows a chemical structure for 1,3-Dimethylbutylamine
- FIG. 9 shows a chemical structure for N,N-Dimethylphenethylamine.
- a vaporizable liquid composition for use with smokeless electronic cigarettes (e-cigarettes).
- a vaporizable liquid composition according to an aspect of the invention includes a vaporizable base.
- the vaporizable base may include an organic solvent, such as vegetable glycerin, propylene glycol, polyethylene glycol or a combination of two or more of such ingredients.
- the vaporizable liquid composition may optionally include a flavoring.
- the flavoring may be a natural flavoring or an artificial flavoring or a combination of natural and artificial flavorings.
- the vaporizable liquid composition may optionally include nicotine.
- the vaporizable liquid composition may further includes one or more stimulants.
- the stimulant or stimulants may serve as a nicotine alternative, enhance a user's energy and/or enhance a user's cognitive function.
- the stimulant composition may comprise 2-Amino-6-methylheptane.
- This stimulant composition may also be known by following alternate nomenclatures and/or names: 1,5-Dimethylhexylamine; 6-Methyl-2-heptylamine; 6-methylheptan-2-amine; 6-Methyl-2-heptanamine; Octodrine; Vaporpac and/or 2-aminoisoheptane. Accordingly, reference to the compound 2-Amino-6-methylheptane herein shall be deemed to include each of these compounds as well.
- the stimulant composition may comprise 2-Amino-5-methylhexane.
- This stimulant composition may also be known by following alternate nomenclatures and/or names: 1,4-Dimethylpentylamine; 1,4-Dimethylamylamine; 5-methyl-2-hexylamine; 2-hexanamine, 5-methyl-; 5-methylhexan-2-amine; and/or pentylamine, 1,4-dimethyl-. Accordingly, reference to the compound 2-Amino-5-methylhexane herein shall be deemed to include each of these compounds as well.
- the stimulant composition may comprise 5-Methyl-2-heptanamine.
- This stimulant composition may also be known by following alternate nomenclatures and/or names: 5-methylheptan-2-amine; 2-Heptanamine, 5-methyl-; 1,4-Dimethylhexylamine and/or 2-Amino-5-methylheptane. Accordingly, reference to the compound 5-Methyl-2-heptanamine herein shall be deemed to include each of these compounds as well.
- the stimulant composition may comprise Higenamine.
- This stimulant composition may also be known by following alternate nomenclatures and/or names: Norcoclaurine and/or Demethylcoclaurine. Accordingly, reference to the compound Higenamine herein shall be deemed to include each of these compounds as well.
- the stimulant composition may comprise 1,3-Dimethylamylamine.
- This stimulant composition may also be known by following alternate nomenclatures and/or names: 1,3-Dimethylpentylamine; 4-methylhexane-2-amine; Methylhexaneamine; 2-Amino-4-methylhexane; Methylhexanamine and/or 1,3-DMAA. Accordingly, reference to the compound 1,3-Dimethylamylamine herein shall be deemed to include each of these compounds as well.
- the stimulant composition may comprise 1,3-Dimethylbutylamine.
- This stimulant composition may also be known by following alternate nomenclatures and/or names: 4-methylpentan-2-amine; 1,3-Dimethylbutanamine; 2-Amino-4-methylpentane; 4-Methyl-2-aminopentane and/or Amp Citrate. Accordingly, reference to the compound 1,3-Dimethylbutylamine herein shall be deemed to include each of these compounds as well.
- the stimulant composition may comprise N,N-Dimethylphenethylamine.
- This stimulant composition may also be known by following alternate nomenclatures and/or names: Dimethylphenethylamine; N,N-Dimethylphenylethylamine; N,N-Dimethyl-N-phenethylamine; N,N-Dimethyl-2-phenylethylamine; N-Phenethyldimethylamine; Dimethyl-phenethyl-amine; phenethyldimethylamine and/or Eria Jarensis.
- the stimulants indicated above may be used alone in a vaporizable liquid composition for electronic cigarettes, or various combinations of the stimulants may be used. Additionally, a vaporizable liquid composition for electronic cigarettes within the scope of the invention may include nicotine as well as one or more of the stimulants indicated above.
- the above-identified stimulants namely 2-Amino-6-methylheptane, 2-Amino-5-methylhexane, 5-Methyl-2-heptanamine, Higenamine, 1,3-Dimethylamylamine, 1,3-Dimethylbutylamine and N,N-Dimethylphenethylamine are known as sympathomimetic stimulants.
- This is in contrast to Nicotine, which is a parasympathomimetic stimulant.
- each of these sympathomimetic stimulants have differentiating chemical structures, and are substantially different in terms of chemical structure (as can be seen from the drawings figures provided herein) as well in effect when compared to the stimulant caffeine.
- sympathomimetic stimulants such as 2-Amino-6-methylheptane, 2-Amino-5-methylhexane, 5-Methyl-2-heptanamine, Higenamine, 1,3-Dimethylamylamine, 1,3-Dimethylbutylamine and N,N-Dimethylphenethylamine, mimic responses due to stimulation of sympathetic nerves.
- These stimulants are able to directly or indirectly activate adrenergic receptors by increasing certain naturally occurring catecholamines, such as norepinephrine (noradrenaline), epinephrine (adrenaline) and dopamine levels.
- Epinephrine (adrenaline) is released by the adrenal glands. Its release into the blood stream increases heart rate and blood flow, resulting in more oxygen and blood flow to muscles, creating an instant source of energy and allowing body to react quickly. The natural secretion of epinephrine is often a result of exercise. Epinephrine has also been shown to play an important role in long term memory function in humans.
- Norepinephrine (noradrenaline), which is also released by the adrenal glands, functions as both a hormone and neurotransmitter in the body.
- the general function of norepinephrine believed to involve mobilizing the brain and body for action. In the brain, norepinephrine increases arousal and alertness, enhances mental cognition and attention, promotes vigilance, and enhances retrieval and formation of memory.
- sympathomimetic stimulants such as Amino-6-methylheptane, 2-Amino-5-methylhexane, 5-Methyl-2-heptanamine, Higenamine, 1,3-Dimethylamylamine, 1,3-Dimethylbutylamine and N,N-Dimethylphenethylamine, when incorporated into a vaporizable liquid composition to be used with an electronic cigarette for inhalation and absorption by a user of the electronic cigarette may enhance a user's energy, mental focus, alertness, overall cognitive function, and physical performance.
- a liquid composition according to an aspect of the invention may be provided, for example in a 30 ml, 60 ml or 100 ml bottle.
- a 30 ml bottle of the vaporizable liquid composition may generally contain no less than 0.001 mg and no more than 100 g of the stimulant composition, for example no less than 1 mg and no more than 2 g of the stimulant composition.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A liquid composition for electronic cigarettes includes a vaporizable base and one or more sympathomimetic stimulants.
Description
- The present invention relates a vaporizable liquid composition for use with smokeless electronic cigarettes (e-cigarettes). More particularly, the invention relates to a vaporizable liquid composition including a vaporizable base and a stimulant.
- U.S. Patent Application Publication No. US 2015/0150303 to Jensen discloses an electronic cigarette liquid including a vaporizable base, a flavoring and a non-nicotine stimulant. The non-nicotine stimulants disclosed in US 2015/0150303 are caffeine, guarana and kola nut.
- Although US 2015/0150303 discloses the incorporation of certain non-nicotine stimulants in a vaporizable composition for electronic cigarettes, there exists a need for a liquid composition for electronic cigarettes incorporating other types of sympathomimetic stimulants, which have distinctly different chemical structures and effects as compared to known stimulant compositions. Moreover, there exists a need for a liquid composition for electronic cigarettes incorporating various stimulants which may enhance energy, mental focus, alertness, overall cognitive function, and physical performance.
- The invention relates to a vaporizable liquid composition for use with smokeless electronic cigarettes (e-cigarettes). More particularly, the invention relates to a vaporizable liquid composition including a vaporizable base and a stimulant.
- A stimulant incorporated into a liquid composition for electronic cigarettes according to an aspect of the invention may be 2-Amino-6-methylheptane.
- A stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be 2-Amino-5-methylhexane.
- A stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be 5-Methyl-2-heptanamine.
- A stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be Higenamine.
- A stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be 1,3-Dimethylamylamine.
- A stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be 1,3-Dimethylbutylamine.
- A stimulant incorporated into a liquid composition for electronic cigarettes according to another aspect of the invention may be N,N-Dimethylphenethylamine.
- An advantage of a liquid composition for electronic cigarettes according to an aspect of the invention is that the liquid composition may include a sympathomimetic stimulant, which may mimic responses due to stimulation of sympathetic nerves and directly or indirectly activate adrenergic receptors by increasing certain naturally occurring catecholamines such as norepinephrine (noradrenaline), epinephrine (adrenaline) and dopamine levels.
- A further advantage of a liquid composition for electronic cigarettes according to an aspect of the invention is that the liquid composition may incorporate a stimulant having the effects of enhancing energy, mental focus, alertness, overall cognitive function, and physical performance.
- Other benefits and features of the present invention will become apparent from the following detailed description con-sidered in connection with the accompanying drawings. It is to be understood, however, that the drawings are designed as an illustration only and not as a definition of the limits of the invention.
- In the drawings:
-
FIG. 1 shows a chemical structure for nicotine; -
FIG. 2 shows a chemical structure for caffeine; -
FIG. 3 shows a chemical structure for 2-Amino-6-methylheptane; -
FIG. 4 shows a chemical structure for 2-Amino-5-methylhexane; -
FIG. 5 shows a chemical structure for 5-Methyl-2-heptanamine; -
FIG. 6 shows a chemical structure for Higenamine; -
FIG. 7 shows a chemical structure for 1,3-Dimethylamylamine; -
FIG. 8 shows a chemical structure for 1,3-Dimethylbutylamine; and -
FIG. 9 shows a chemical structure for N,N-Dimethylphenethylamine. - The invention relates to a vaporizable liquid composition for use with smokeless electronic cigarettes (e-cigarettes). A vaporizable liquid composition according to an aspect of the invention includes a vaporizable base. The vaporizable base may include an organic solvent, such as vegetable glycerin, propylene glycol, polyethylene glycol or a combination of two or more of such ingredients.
- The vaporizable liquid composition may optionally include a flavoring. The flavoring may be a natural flavoring or an artificial flavoring or a combination of natural and artificial flavorings.
- The vaporizable liquid composition may optionally include nicotine.
- The vaporizable liquid composition may further includes one or more stimulants. The stimulant or stimulants may serve as a nicotine alternative, enhance a user's energy and/or enhance a user's cognitive function.
- In one aspect of the invention, the stimulant composition may comprise 2-Amino-6-methylheptane. This stimulant composition may also be known by following alternate nomenclatures and/or names: 1,5-Dimethylhexylamine; 6-Methyl-2-heptylamine; 6-methylheptan-2-amine; 6-Methyl-2-heptanamine; Octodrine; Vaporpac and/or 2-aminoisoheptane. Accordingly, reference to the compound 2-Amino-6-methylheptane herein shall be deemed to include each of these compounds as well.
- In another aspect of the invention, the stimulant composition may comprise 2-Amino-5-methylhexane. This stimulant composition may also be known by following alternate nomenclatures and/or names: 1,4-Dimethylpentylamine; 1,4-Dimethylamylamine; 5-methyl-2-hexylamine; 2-hexanamine, 5-methyl-; 5-methylhexan-2-amine; and/or pentylamine, 1,4-dimethyl-. Accordingly, reference to the compound 2-Amino-5-methylhexane herein shall be deemed to include each of these compounds as well.
- In another aspect of the invention, the stimulant composition may comprise 5-Methyl-2-heptanamine. This stimulant composition may also be known by following alternate nomenclatures and/or names: 5-methylheptan-2-amine; 2-Heptanamine, 5-methyl-; 1,4-Dimethylhexylamine and/or 2-Amino-5-methylheptane. Accordingly, reference to the compound 5-Methyl-2-heptanamine herein shall be deemed to include each of these compounds as well.
- In another aspect of the invention, the stimulant composition may comprise Higenamine. This stimulant composition may also be known by following alternate nomenclatures and/or names: Norcoclaurine and/or Demethylcoclaurine. Accordingly, reference to the compound Higenamine herein shall be deemed to include each of these compounds as well.
- In another aspect of the invention, the stimulant composition may comprise 1,3-Dimethylamylamine. This stimulant composition may also be known by following alternate nomenclatures and/or names: 1,3-Dimethylpentylamine; 4-methylhexane-2-amine; Methylhexaneamine; 2-Amino-4-methylhexane; Methylhexanamine and/or 1,3-DMAA. Accordingly, reference to the compound 1,3-Dimethylamylamine herein shall be deemed to include each of these compounds as well.
- In another aspect of the invention, the stimulant composition may comprise 1,3-Dimethylbutylamine. This stimulant composition may also be known by following alternate nomenclatures and/or names: 4-methylpentan-2-amine; 1,3-Dimethylbutanamine; 2-Amino-4-methylpentane; 4-Methyl-2-aminopentane and/or Amp Citrate. Accordingly, reference to the compound 1,3-Dimethylbutylamine herein shall be deemed to include each of these compounds as well.
- In another aspect of the invention, the stimulant composition may comprise N,N-Dimethylphenethylamine. This stimulant composition may also be known by following alternate nomenclatures and/or names: Dimethylphenethylamine; N,N-Dimethylphenylethylamine; N,N-Dimethyl-N-phenethylamine; N,N-Dimethyl-2-phenylethylamine; N-Phenethyldimethylamine; Dimethyl-phenethyl-amine; phenethyldimethylamine and/or Eria Jarensis.
- The stimulants indicated above may be used alone in a vaporizable liquid composition for electronic cigarettes, or various combinations of the stimulants may be used. Additionally, a vaporizable liquid composition for electronic cigarettes within the scope of the invention may include nicotine as well as one or more of the stimulants indicated above.
- The above-identified stimulants, namely 2-Amino-6-methylheptane, 2-Amino-5-methylhexane, 5-Methyl-2-heptanamine, Higenamine, 1,3-Dimethylamylamine, 1,3-Dimethylbutylamine and N,N-Dimethylphenethylamine are known as sympathomimetic stimulants. This is in contrast to Nicotine, which is a parasympathomimetic stimulant. Moreover, each of these sympathomimetic stimulants have differentiating chemical structures, and are substantially different in terms of chemical structure (as can be seen from the drawings figures provided herein) as well in effect when compared to the stimulant caffeine.
- In particular, sympathomimetic stimulants, such as 2-Amino-6-methylheptane, 2-Amino-5-methylhexane, 5-Methyl-2-heptanamine, Higenamine, 1,3-Dimethylamylamine, 1,3-Dimethylbutylamine and N,N-Dimethylphenethylamine, mimic responses due to stimulation of sympathetic nerves. These stimulants are able to directly or indirectly activate adrenergic receptors by increasing certain naturally occurring catecholamines, such as norepinephrine (noradrenaline), epinephrine (adrenaline) and dopamine levels.
- Dopamine functions as a neurotransmitter in the brain. Increasing dopamine levels may be beneficial as dopamine plays a vital role in bodily motor control, executive functions like mental processes and skills, motivation, mood, arousal and reward. Low dopamine levels can lead to fatigue, addictive behavior, mood swings, memory loss and a lack of motivation.
- Epinephrine (adrenaline) is released by the adrenal glands. Its release into the blood stream increases heart rate and blood flow, resulting in more oxygen and blood flow to muscles, creating an instant source of energy and allowing body to react quickly. The natural secretion of epinephrine is often a result of exercise. Epinephrine has also been shown to play an important role in long term memory function in humans.
- Norepinephrine (noradrenaline), which is also released by the adrenal glands, functions as both a hormone and neurotransmitter in the body. The general function of norepinephrine believed to involve mobilizing the brain and body for action. In the brain, norepinephrine increases arousal and alertness, enhances mental cognition and attention, promotes vigilance, and enhances retrieval and formation of memory.
- For these reasons, sympathomimetic stimulants, such as Amino-6-methylheptane, 2-Amino-5-methylhexane, 5-Methyl-2-heptanamine, Higenamine, 1,3-Dimethylamylamine, 1,3-Dimethylbutylamine and N,N-Dimethylphenethylamine, when incorporated into a vaporizable liquid composition to be used with an electronic cigarette for inhalation and absorption by a user of the electronic cigarette may enhance a user's energy, mental focus, alertness, overall cognitive function, and physical performance.
- A liquid composition according to an aspect of the invention may be provided, for example in a 30 ml, 60 ml or 100 ml bottle. In terms of dosing, a 30 ml bottle of the vaporizable liquid composition may generally contain no less than 0.001 mg and no more than 100 g of the stimulant composition, for example no less than 1 mg and no more than 2 g of the stimulant composition.
- While a number of embodiments of the present invention have been shown and described, it is obvious that many changes and modifications may be made thereunto without departing from the spirit and scope of the invention.
Claims (7)
1. A liquid composition for electronic cigarettes comprising:
a vaporizable base; and
2-Amino-6-methylheptane.
2. A liquid composition for electronic cigarettes comprising:
a vaporizable base; and
2-Amino-5-methylhexane.
3. A liquid composition for electronic cigarettes comprising:
a vaporizable base; and
5-Methyl-2-heptanamine.
4. A liquid composition for electronic cigarettes comprising:
a vaporizable base; and
Higenamine.
5. A liquid composition for electronic cigarettes comprising:
a vaporizable base; and
1,3-Dimethylamylamine.
6. A liquid composition for electronic cigarettes comprising:
a vaporizable base; and
1,3-Dimethylbutylamine.
7. A liquid composition for electronic cigarettes comprising:
a vaporizable base; and
N,N-Dimethylphenethylamine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/901,508 US20190254336A1 (en) | 2018-02-21 | 2018-02-21 | Liquid composition for electronic cigarettes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/901,508 US20190254336A1 (en) | 2018-02-21 | 2018-02-21 | Liquid composition for electronic cigarettes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20190254336A1 true US20190254336A1 (en) | 2019-08-22 |
Family
ID=67616346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/901,508 Abandoned US20190254336A1 (en) | 2018-02-21 | 2018-02-21 | Liquid composition for electronic cigarettes |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US20190254336A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060223855A1 (en) * | 2004-12-22 | 2006-10-05 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20140113826A1 (en) * | 2012-10-24 | 2014-04-24 | Celanese Acetate Llc | Polysaccharide ester microspheres and methods and articles relating thereto |
-
2018
- 2018-02-21 US US15/901,508 patent/US20190254336A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060223855A1 (en) * | 2004-12-22 | 2006-10-05 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20140113826A1 (en) * | 2012-10-24 | 2014-04-24 | Celanese Acetate Llc | Polysaccharide ester microspheres and methods and articles relating thereto |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Farsalinos et al. | Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices | |
| Cohen et al. | Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking | |
| JP2017501714A (en) | Liquid composition for electronic cigarette | |
| US20150150303A1 (en) | Electronic cigarette liquid and method of use to reduce, replace, or eliminate nicotine intake/addiction | |
| CN101933654A (en) | Cigarette liquid for tooth whitening and strengthening health care electronic cigarettes | |
| Hoyt | Cigarette smoking: nicotine, carbon monoxide, and the physiological effects on exercise responses | |
| US20190254336A1 (en) | Liquid composition for electronic cigarettes | |
| AT501560A1 (en) | USE OF HERB CIGARETTES | |
| CN101889734A (en) | Water storage device for cigarette filter tip | |
| Mishra | Are e-cigarettes beneficial for public health: Hume's guillotine–The debate continues? | |
| US20150272879A1 (en) | Essential oil and herbal extract mist composition and method of delivery | |
| JP2005218498A (en) | Aroma suction pipe | |
| Aicher et al. | Electronic cigarettes: questions in the mist | |
| Postolache et al. | ELECTRONIC CIGARETTE–A WAY OF SMOKING CESSATION? | |
| Lin et al. | E-Cigarette: Friend or Foe? | |
| Fins | Baseball and bioethics revisited: The pitch clock and age discrimination in a timeless pastime | |
| KR102733453B1 (en) | manufacturing method liquefied composition of electronic cigarette for well vaping | |
| JP6581151B2 (en) | Smoking cessation promoter and portable smoking cessation promoting device | |
| KR20150093935A (en) | Aromatherapy Health electronic cigarette cartridges. | |
| US8287922B2 (en) | Vaporized Lobelia product and method of use | |
| Sharma et al. | Supplementary Materials: Motivations and Limitations Associated with Vaping Among People with Mental Illness: A Qualitative Analysis of Reddit Discussions | |
| Greeshma et al. | ROLE OF LAVANGA (SYZYGIUM AROMATICUM MERR. PERRY) IN GRAHANI ROGA | |
| WO2025099687A1 (en) | Liquid composition for e-cigarette and e-cigarette containing such composition | |
| Kimber | Electronic Cigarettes: Puffing Topography and Self-titration-the Importance of Nicotine Concentration, User Experience and Device Characteristics | |
| DE202010010189U1 (en) | Caffeine-containing concentrate solution in a carrier liquid which can be thermally evaporated with a special electrically operated device similar to a cigarette and this caffeine-containing vapor can be inhaled |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: CMBT HOLDINGS INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:YANDOLI, CHRISTOPHER;REEL/FRAME:044991/0864 Effective date: 20180221 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |